Changes in Neisseria meningitidis Disease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal Disease

Cohn, Amanda C., MacNeil, Jessica R., Harrison, Lee H., Hatcher, Cynthia, Theodore, Jordan, Schmidt, Mark, Pondo, Tracy, Arnold, Kathryn E. +15 more·2010·Clinical Infectious Diseases
DOI 10.1086/649209

Cited by (345)

Items 101–200 of 345

  1. A Decade of Invasive Meningococcal Disease Surveillance in Poland
    Anna Skoczyńska, Izabela Waśko, Alicja Kuch, Marcin Kadłubowski, Agnieszka Gołębiewska, Małgorzata Foryś, Marlena Markowska, Patrycja Ronkiewicz, Katarzyna Wasiak, Aleksandra Kozińska et al. · 2013 · PLoS ONE
  2. A review of guidance on immunization in persons with defective or deficient splenic function
    Ernest Piotr Kuchar, Katarzyna Miśkiewicz, Monika Karlikowska‐Skwarnik · 2015 · British Journal of Haematology
  3. The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine
    Ghassan S. Dbaibo, Noel G. Macalalad, Mari Rose Aplasca-De Los Reyes, Efren M. Dimaano, Véronique Bianco, Yaela Baine, Jacqueline M. Miller · 2012 · Human Vaccines & Immunotherapeutics
  4. Immunogenicity and Safety of a Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) Administered to Adults Aged 56 Years and Older: Results of an Open-Label, Randomized, Controlled Trial
    Ghassan S. Dbaibo, Nabil K. El-Ayoubi, Soha Ghanem, Farah Hajar, Véronique Bianco, Jacqueline M. Miller, Narcisa Elena Mesaros · 2013 · Drugs & Aging
  5. Changing epidemiology of meningococcal disease in Europe from the mid-20th to the early 21st Century
    Paula Kriz, Heather Wieffer, Katsiaryna Holl, Mats Rosenlund, S Budhia, Andrew Vyse · 2011 · Expert Review of Vaccines
  6. Two cross‐reactive monoclonal antibodies recognize overlapping epitopes on Neisseria meningitidis factor H binding protein but have different functional properties
    Agnese Faleri, Laura Santini, Sébastien Brier, Werner Pansegrau, Paola Lo Surdo, Maria Scarselli, Francesca Buricchi, Gianfranco Volpini, Alessia Genovese, Stijn van der Veen et al. · 2013 · The FASEB Journal
  7. Meningococcal Vaccines: Current Issues and Future Strategies
    Amanda C. Cohn, Lee H. Harrison · 2013 · Drugs
  8. Whole-Genome Sequencing for Characterization of Capsule Locus and Prediction of Serogroup of Invasive Meningococcal Isolates
    Henju Marjuki, Nadav Topaz, Lorraine D. Rodriguez‐Rivera, Edward Ramos, Caelin Cubeñas-Potts, Alexander Junxiang Chen, Adam C. Retchless, Gregory Doho, Xin Wang · 2018 · Journal of Clinical Microbiology
  9. Changes in the Population Structure of InvasiveNeisseria meningitidisin the United States After Quadrivalent Meningococcal Conjugate Vaccine Licensure
    Xin Wang, Kathleen A. Shutt, Jeni T. Vuong, Amanda C. Cohn, Jessica R. MacNeil, Susanna E. Schmink, Brian D. Plikaytis, Nancy E. Messonnier, Lee H. Harrison, Thomas A. Clark et al. · 2015 · The Journal of Infectious Diseases
  10. A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants
    Federico Martinón‐Torres, Francisco Giménez‐Sánchez, Enrique Bernaola-Iturbe, Javier Díez‐Domingo, Qin Li Jiang, John L. Perez · 2014 · Vaccine
  11. Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience
    Jacqueline M. Miller, Narcisa Elena Mesaros, Marie Van der Wielen, Yaela Baine · 2011 · Advances in Preventive Medicine
  12. Meningococcal Carriage Among Georgia and Maryland High School Students
    Lee H. Harrison, Kathleen A. Shutt, Kathryn E. Arnold, Eric J. Stern, Tracy Pondo, Julia A. Kiehlbauch, Robert A. Myers, Rosemary A. Hollick, Susanna E. Schmink, Marianne S. Vello et al. · 2014 · The Journal of Infectious Diseases
  13. Economic evaluation of meningococcal vaccines: considerations for the future
    Hannah Christensen, Hareth Al‐Janabi, Pierre Lévy, Maarten Jacobus Postma, David E. Bloom, Paolo Landa, Oliver Damm, DAVID M. SALISBURY, Javier Díez‐Domingo, Adrian Towse et al. · 2019 · The European Journal of Health Economics
  14. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT)
    Lars Jørgen Østergaard, Marie Van der Wielen, Véronique Bianco, Jacqueline M. Miller · 2012 · International Journal of Infectious Diseases
  15. Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies
    Marco Aurélio Palazzi Sáfadi, E. David G. McIntosh · 2011 · Expert Review of Vaccines
  16. Pediatricians’ Preferences for Infant Meningococcal Vaccination
    Christine M. Poulos, F. Reed Johnson, Girishanthy Krishnarajah, Andrea M. Anonychuk, Derek A. Misurski · 2015 · Value in Health
  17. Bivalent rLP2086 Vaccine (Trumenba®): A Review in Active Immunization Against Invasive Meningococcal Group B Disease in Individuals Aged 10–25 Years
    Matt Shirley, Sohita Dhillon · 2015 · BioDrugs
  18. Vaccines for prevention of group B meningococcal disease: Not your father's vaccines
    Lee H. Harrison · 2015 · Vaccine
  19. Management of the Non–Toxic-Appearing Acutely Febrile Child: A 21st Century Approach
    Ravi R. Jhaveri, Carrie L. Byington, Jerome O. Klein, Eugene D. Shapiro · 2011 · The Journal of Pediatrics
  20. Changes in Neisseria meningitidis Disease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal Disease
    Diederik van de Beek · 2010 · Yearbook of Neurology and Neurosurgery
  21. Antibody Persistence After Primary and Booster Doses of a Quadrivalent Meningococcal Conjugate Vaccine in Adolescents
    Roger P. Baxter, Keith S. Reisinger, Stanley L. Block, Sandra Percell, Tatjana M. Odrljin, Peter M Dull, Igor V. Smolenov · 2014 · The Pediatric Infectious Disease Journal
  22. The Changing Epidemiology of Meningococcal Disease in Quebec, Canada, 1991–2011: Potential Implications of Emergence of New Strains
    Rodica Gilca, Geneviève Deceuninck, Brigitte Lefebvre, Raymond S. W. Tsang, Rachid Amini, Vladimir Gîlca, Monique Douville-Fradet, France Markowski, Philippe De Wals · 2012 · PLoS ONE
  23. The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative
    Marco Aurélio Palazzi Sáfadi, Luz Elena Espinosa de los Monteros, Eduardo Luis López, Xavier Sáez‐Llorens, Ana Paula Lemos, Sarbelio Moreno‐Espinosa, Silvia González Ayala, Juan Pablo Torres, José Cássio de Moraes, Julio A. Vázquez · 2013 · Expert Review of Vaccines
  24. Meningococcal pneumonia
    Matthias Gerhard Vossen, Dieter Mitteregger, Christoph Steininger · 2016 · Vaccine
  25. Severe Meningococcal Infection
    Paul A. Campsall, Kevin B. Laupland, Daniel J. Niven · 2013 · Critical Care Clinics
  26. Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France
    Muhamed‐Kheir Taha, Julio Cesar Hawkins, Paul Liberator, Ala‐Eddine Deghmane, Lubomira Andrew, Hao Li, Thomas R. Jones, Lisa Kristin McNeil, Robert E. O’Neill, John L. Perez et al. · 2017 · Vaccine
  27. Prevention and control of meningococcal outbreaks: The emerging role of serogroup B meningococcal vaccines
    Ernesto Oviedo‐Orta, Sohail Ahmed, Rino Rappuoli, STEVEN B. BLACK · 2015 · Vaccine
  28. Evaluation of use of reading comprehension strategies to improve reading comprehension of adult college students with acquired brain injury
    Gina G. Griffiths, McKay Moore Sohlberg, Cecilia J. Kirk, Stephen F. Fickas, Gina Biancarosa · 2015 · Neuropsychological Rehabilitation
  29. Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine
    Timo Vesikari, Aino Forstén, Véronique Bianco, Marie Van der Wielen, Jacqueline M. Miller · 2015 · Human Vaccines & Immunotherapeutics
  30. Capsular polysaccharide vaccine for Group B Neisseria meningitidis , Escherichia coli K1, and Pasteurella haemolytica A2
    John B. Robbins, Rachel Schneerson, Gui-lin Xie, Lars Åke Hanson, Mark A. Miller · 2011 · Proceedings of the National Academy of Sciences
  31. New frontiers in meningococcal vaccines
    Annaliesa S. Anderson, Kathrin Ute Jansen, Joseph Eiden · 2011 · Expert Review of Vaccines
  32. A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults
    Lars Jørgen Østergaard, Gregg H. Lucksinger, Judith Absalon, Johannes F. Beeslaar, Joseph J. Eiden, Kathrin Ute Jansen, Laura J. York, Angela Quinn, Mette E. Graversen, John L. Perez · 2016 · Vaccine
  33. Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents
    Xavier Sáez‐Llorens, Diana Catalina Aguilera Vaca, Katia Abarca V, Emmanuelle Maho, María Gabriela Graña, Esther Heijnen, Igor V. Smolenov, Peter M Dull · 2015 · Human Vaccines & Immunotherapeutics
  34. Meningococcal disease epidemiology in Brazil (2005–2018) and impact of MenC vaccination
    Altacílio Aparecido Nunes, Ariane de Jesus Lopes de Abreu, Otávio Augusto Leite Cintra, Monica A.C.T. Cintra, Eduardo Barbosa Coelho, Eliana Nogueira Castro de Barros · 2020 · Vaccine
  35. Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age
    Terry M. Nolan, Michael D. Nissen, Aftab Naz, Julie S. Shepard, Lisa Bedell, Matthew J. Hohenboken, Tatjana M. Odrljin, Peter M Dull · 2013 · Human Vaccines & Immunotherapeutics
  36. Safety of Quadrivalent Meningococcal Conjugate Vaccine in 11- to 21-Year-Olds
    Hung Fu Tseng, Lina S. Sy, Bradley K. Ackerson, Rulin C. Hechter, Sara Yee Tartof, Mendel D. M. Haag, Jeffrey M. Slezak, Yi Luo, Christine A. Fischetti, Harp S. Takhar et al. · 2016 · PEDIATRICS
  37. Neisseria meningitidis (Meningococcus)
    Dan M. Granoff, Janet R. Gilsdorf · 2011 · Elsevier eBooks
  38. Does Binding of Complement Factor H to the Meningococcal Vaccine Antigen, Factor H Binding Protein, Decrease Protective Serum Antibody Responses?
    Dan M. Granoff, Sanjay Ram, Peter T. Beernink · 2013 · Clinical and Vaccine Immunology
  39. Immunogenicity and Safety of H influenzae Type b–N meningitidis C/Y Conjugate Vaccine in Infants
    Kristina A. Bryant, Gary S. Marshall, Colin D. Marchant, Noris Pavia-Ruiz, Terry M. Nolan, Stephen B. Rinderknecht, Mark M. Blatter, Emmanuel Aris, Pascal Lestrate, Dominique Boutriau et al. · 2011 · PEDIATRICS
  40. Immunogenicity and Safety of an Investigational Combined Haemophilus influenzae Type B-Neisseria meningitidis Serogroups C and Y-Tetanus Toxoid Conjugate Vaccine
    Terry M. Nolan, Peter Richmond, Helen Siobhan Marshall, Jodie McVernon, Karyn Alexander, Narcisa Elena Mesaros, Emmanuel Aris, Jacqueline M. Miller, JAN T. POOLMAN, Dominique Boutriau · 2010 · The Pediatric Infectious Disease Journal
  41. A critical appraisal of the recommendations for the use of meningococcal conjugate vaccines
    Marco Aurélio Palazzi Sáfadi, Eitan Naaman Berezin, Gabriel Wolf Oselka · 2012 · Jornal de Pediatria
  42. Addressing the Challenges of Serogroup B Meningococcal Disease Outbreaks on Campuses
    William Schaffner, Carol J. Baker, Lynn Bozof, Jeffrey P. Engel, Paul A. Offit, James C. Turner · 2014 · Infectious Diseases in Clinical Practice
  43. Increase of meningococcal serogroup Y cases in Europe: A reason for concern?
    Michael Bröker, Susanne Jacobsson, Lisa M DeTora, David Pace, Muhamed‐Kheir Taha · 2012 · Human Vaccines & Immunotherapeutics
  44. History of Meningococcal Outbreaks in the United States: Implications for Vaccination and Disease Prevention
    Bruce Atkinson, Ashesh J. Gandhi, Paul Balmer · 2016 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  45. Population structure of invasive Neisseria meningitidis in the United States, 2011–15
    Caelin Cubeñas-Potts, Sandeep J. Joseph, How-Yi Chang, Alexander Junxiang Chen, Jeni T. Vuong, Fang Hu, Laurel T. Jenkins, Susanna E. Schmink, Amy E. Blain, Jessica R. MacNeil et al. · 2018 · Journal of Infection
  46. Immunogenicity and Safety of a Meningococcal Serogroup A, C, Y and W Glycoconjugate Vaccine, ACWY-TT
    Helen Findlow, Ray Borrow · 2013 · Advances in Therapy
  47. Critical appraisal of a quadrivalent CRM197 conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo®) in the context of treatment and prevention of invasive disease
    Michael Broeker, Lisa M DeTora, C Cooper, Stoddard · 2011 · Infection and Drug Resistance
  48. Impaired Immunogenicity of a Meningococcal Factor H-Binding Protein Vaccine Engineered To Eliminate Factor H Binding
    Peter T. Beernink, Jutamas Shaughnessy, Sanjay Ram, Dan M. Granoff · 2010 · Clinical and Vaccine Immunology
  49. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration
    Roberto Gasparini, Miguel Tregnaghi, Pavitra Keshavan, Ellen Ypma, Linda Han, Igor V. Smolenov · 2015 · The Pediatric Infectious Disease Journal
  50. Serum Bactericidal Antibody Responses of Students Immunized With a Meningococcal Serogroup B Vaccine in Response to an Outbreak on a University Campus
    Eduardo Lujan, Kathleen Winter, Jillandra Rovaris, Qin Liu, Dan M. Granoff · 2017 · Clinical Infectious Diseases
  51. Five-year Antibody Persistence and Booster Response After 1 or 2 Doses of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children
    Nicola P. Klein, Yaela Baine, Devayani A. Kolhe, Carmen I. Baccarini, Jacqueline M. Miller, Marie Van der Wielen · 2016 · The Pediatric Infectious Disease Journal
  52. Prevention of Meningococcal Infection in the United States: Current Recommendations and Future Considerations
    Carol J. Baker · 2016 · Journal of Adolescent Health
  53. The investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults
    Mari Rose Aplasca-De Los Reyes, Efren M. Dimaano, Noel G. Macalalad, Ghassan S. Dbaibo, Véronique Bianco, Yaela Baine, Jacqueline M. Miller · 2012 · Human Vaccines & Immunotherapeutics
  54. Observed parent–child relationship quality predicts antibody response to vaccination in children
    Thomas G. O’Connor, Hongyue Wang, Jan A. Moynihan, Peter A. Wyman, Jennifer A. Carnahan, Gerry Lofthus, Sally A. Quataert, Melissa Bowman, Anne S. Burke, Mary T. Caserta · 2015 · Brain Behavior and Immunity
  55. Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines
    Leszek Szenborn, Stan L. Block, Teresa Jackowska, Ryszard Konior, Diego D’Agostino, Igor V. Smolenov, Daniela Toneatto, Jo Anne Welsch · 2018 · The Pediatric Infectious Disease Journal
  56. Meningococcal group A, C, Y and W-135 conjugate vaccine
    Lee H. Harrison, Nitin Mohan, Peter N. Kirkpatrick · 2010 · Nature Reviews Drug Discovery
  57. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: Results of an open-label, randomized, phase 3b controlled study in healthy infants
    Arturo Abdelnour, Peter E. Silas, Marta Raquel Valdés Lamas, Carlos Fernándo Grazioso Aragón, Nan‐Chang Chiu, Cheng‐Hsun Chiu, Teobaldo Herrera Acuña, Tirza De León Castrejón, Allen Izu, Tatjana M. Odrljin et al. · 2014 · Vaccine
  58. The adjuvant effect of TLR7 agonist conjugated to a meningococcal serogroup C glycoconjugate vaccine
    Agnese Donadei, Cristiana Balocchi, Francesca Mancini, Daniela Proietti, Simona Gallorini, Derek T. O’Hagan, Ugo D’Oro, Francesco Berti, Barbara C. Baudner, Roberto Adamo · 2016 · European Journal of Pharmaceutics and Biopharmaceutics
  59. Epidemiology and Meningococcal Serogroup Distribution in the United States
    Jody Henry Hershey, William P. Hitchcock · 2010 · Clinical Pediatrics
  60. Persistence of Meningococcal Antibodies and Response to a Third Dose After a Two-dose Vaccination Series with Investigational MenABCWY Vaccine Formulations in Adolescents
    Xavier Sáez‐Llorens, Diana Catalina Aguilera Vaca, Katia Abarca V, Emmanuelle Maho, Linda Han, Igor V. Smolenov, Peter M Dull · 2015 · The Pediatric Infectious Disease Journal
  61. Challenges and opportunities for meningococcal vaccination in the developing world
    Rouba Shaker, Danielle Fayad, Ghassan S. Dbaibo · 2018 · Human Vaccines & Immunotherapeutics
  62. Prevalence, Associated Risk Factors and Rifampicin Resistance Pattern of Pulmonary Tuberculosis Among Children at Debre Markos Referral Hospital, Northwest, Ethiopia
    Mulusew Liyew Ayalew, Wubet Birhan, Abiye Tigabu, Baye Gelaw Tarekegn · 2020 · Infection and Drug Resistance
  63. Outbreaks of meningococcal B infection and the 4CMenB vaccine: historical and future perspectives
    Jane Whelan, Stefania Bambini, Alessia Biolchi, Brunella Brunelli, Mirna Robert-Du Ry van Beest Holle · 2015 · Expert Review of Vaccines
  64. Effectiveness of Immunoprophylaxis in Suppressing Carriage of Neisseria Meningitidis in the Military Environment
    Krzysztof Korzeniewski, Anna Skoczyńska, Aneta Guzek, Monika Konior, Andrzej Chciałowski, Izabela Waśko, Marlena Markowska, Ewa Zwolińska · 2014 · Advances in experimental medicine and biology
  65. Invasive meningococcal disease in children in Ireland, 2001–2011
    Cilian Ó Maoldomhnaigh, Richard John Drew, Patrick J. Gavin, MARY T. CAFFERKEY, KARINA M. BUTLER · 2016 · Archives of Disease in Childhood
  66. Adolescents trust physicians for vaccine information more than their parents or religious leaders
    Daisy S. Griffin, George Muhlbauer, Daniel O. Griffin · 2018 · Heliyon
  67. Commentary
    Dan M. Granoff · 2012 · The Pediatric Infectious Disease Journal
  68. Meningococcal Disease
    Sarah A. Mbaeyi, Amanda C. Cohn, Matthew E. Coldiron · 2018 · Cambridge University Press eBooks
  69. The role of Toll-like receptor 4 polymorphisms in vaccine immune response
    Paolo Pellegrino, Felicia Stefania Falvella, Stefania Cheli, Cristiana Perrotta, Emilio Clementi, Sonia Radice · 2015 · The Pharmacogenomics Journal
  70. Importance of circulating antibodies in protection against meningococcal disease
    Kim S. Erlich, Blaise L. Congeni · 2012 · Human Vaccines & Immunotherapeutics
  71. Association between population prevalence of smoking and incidence of meningococcal disease in Norway, Sweden, Denmark and the Netherlands between 1975 and 2009: a population-based time series analysis
    Gunnstein Norheim, Manish Sadarangani, Omar Omar, Ly‐Mee Yu, Kåre Mølbak, Michael Frantz Howitz, Per Olcén, Margaretha Haglund, Arie VAN DER ENDE, Andrew John Pollard · 2014 · BMJ Open
  72. Basic Processes in Salmonella -Host Interactions: Within-Host Evolution and the Transmission of the Virulent Genotype
    Médéric Diard, Wolf‐Dietrich Hardt · 2017 · Microbiology Spectrum
  73. Hospital Costs, Length of Stay and Mortality Associated with Childhood, Adolescent and Young Adult Meningococcal Disease in the US
    Keith L. Davis, TIMOTHY J. BELL, Jacqueline M. Miller, Derek A. Misurski, Bela Bapat · 2011 · Applied Health Economics and Health Policy
  74. Intracardiac left atrial tuberculoma in an eleven-month-old infant: case report
    Massimiliano Cantinotti, Marina De Gaudio, Maurizio de Martino, Nadia Assanta, Riccardo Moschetti, Giuseppina Veneruso, Maura Crocetti, Bruno Murzi, Elena Chiappini, Luisa Galli · 2011 · BMC Infectious Diseases
  75. Neisseria meningitidisserogroup B bivalent factor H binding protein vaccine
    Nathan James Brendish, Robert Charles Read · 2015 · Expert Review of Vaccines
  76. Epidemiological analysis on two decades of hospitalisations for meningitis in the United States
    Paolo Pellegrino, Carla Carnovale, Valentina Perrone, Dionigi Salvati, Marta Gentili, Tatiana Brusadelli, Stefania Antoniazzi, Marco Pozzi, Sonia Radice, Emilio Clementi · 2014 · European Journal of Clinical Microbiology & Infectious Diseases
  77. Neisseria meningitidis
    David S. Stephens, Michael A. Apicella · 2015 · Elsevier eBooks
  78. Risk Factors for Serogroup C Meningococcal Disease during Outbreak among Men who Have Sex with Men, New York City, New York, USA
    Alison Ridpath, Sharon K. Greene, Byron F. Robinson, Don Weiss, the Meningococcal Investigation Team · 2015 · Emerging infectious diseases
  79. Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa
    Rolando Pajón, Andrew M. Fergus, Dan M. Granoff · 2013 · PLoS ONE
  80. An outbreak of serogroup C (ST-11) meningococcal disease in Tijuana, Mexico
    Enrique Chacón‐Cruz, Luz Elena Espinosa de los Monteros, Samuel Navarro-Álvarez, Jose Luis Aranda-Lozano, Maria Luisa Volker-Soberanes, Rosa Maria Rivas-Landeros, Ariadna Anette Alvelais-Arzamendi, Julio A. Vázquez · 2014 · Therapeutic Advances in Vaccines
  81. Meningococcal Factor H Binding Protein Vaccine Antigens with Increased Thermal Stability and Decreased Binding of Human Factor H
    Raffaella Rossi, Monica Konar, Peter T. Beernink · 2016 · Infection and Immunity
  82. Immunization of newborns with bacterial conjugate vaccines
    Anita H.J. van den Biggelaar, William S. Pomat · 2012 · Vaccine
  83. Emerging and Reemerging Neurologic Infections
    Felicia C. Chow, Carol Ann Glaser · 2014 · The Neurohospitalist
  84. Vaccinations in asplenic adults
    Rhonda J. Hammerquist, Kimberly A. Messerschmidt, April A. Pottebaum, Thaddaus R. Hellwig · 2016 · American Journal of Health-System Pharmacy
  85. Multivalent meningococcal serogroup B vaccines: challenges in predicting protection and measuring effectiveness
    JAN T. POOLMAN, Peter Richmond · 2015 · Expert Review of Vaccines
  86. Meningococcal conjugate vaccines: optimizing global impact
    Andrew Terranella, Amanda C. Cohn, Clark · 2011 · Infection and Drug Resistance
  87. Resurgence of Vaccine-Preventable Diseases in the United States: Anesthetic and Critical Care Implications
    Grete H. Porteous, Neil A. Hanson, Lila A Sueda, Carli D. Hoaglan, Aaron B. Dahl, Brooks B. Ohlson, Brian E. Schmidt, Chia C. Wang, R. Eliot Fagley · 2016 · Anesthesia & Analgesia
  88. The Impact of Meningococcal Polymerase Chain Reaction Testing on Laboratory Confirmation of Invasive Meningococcal Disease
    Richard John Drew, Cilian Ó Maoldomhnaigh, Patrick J. Gavin, Nicola O’ Sullivan, KARINA M. BUTLER, MARY T. CAFFERKEY · 2011 · The Pediatric Infectious Disease Journal
  89. Investigating the immunodominance of carbohydrate antigens in a bivalent unimolecular glycoconjugate vaccine against serogroup A and C meningococcal disease
    Roberto Adamo, Alberto Nilo, Carole Harfouche, Barbara Brogioni, Simone Pecetta, Giulia Brogioni, Evita Balducci, Vittoria Pinto, Sara Filippini, Elena Mori et al. · 2014 · Glycoconjugate Journal
  90. Novel Intervention in the Aging Population: A Primary Meningococcal Vaccine Inducing Protective IgM Responses in Middle-Aged Adults
    Marieke van der Heiden, Annemieke M. H. Boots, Axel A. Bonačić Marinović, Lia de Rond, Marjan van Maurik, Irina Tcherniaeva, Guy A. M. Berbers, Anne‐Marie Buisman · 2017 · Frontiers in Immunology
  91. Acute Meningitis
    Allan R. Tunkel, Diederik van de Beek, W. Michael Scheld · 2015 · Elsevier eBooks
  92. fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations
    Serena Giuntini, David M. Vu, Dan M. Granoff · 2013 · Vaccine
  93. Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents
    Beatriz P. Quiambao, Ashish Bavdekar, Anand Prakash Dubey, Hemant Jain, Devayani A. Kolhe, Véronique Bianco, Jacqueline M. Miller, Marie Van der Wielen · 2017 · Human Vaccines & Immunotherapeutics
  94. Serogroup B Meningococcus Outbreaks, Prevalence, and the Case for Standard Vaccination
    James Grogan, Karen L. Roos · 2017 · Current Infectious Disease Reports
  95. Antibiotic Resistance in Neisseria
    Margaret C. Bash, Kathryn Matthias · 2017 · Springer eBooks
  96. Rifaximin in the Treatment of Irritable Bowel Syndrome
    David J. Farrell · 2013 · Journal of Clinical Gastroenterology
  97. A Mutant Library Approach to Identify Improved Meningococcal Factor H Binding Protein Vaccine Antigens
    Monica Konar, Raffaella Rossi, Mboto Helen Walter, Rolando Pajón, Peter T. Beernink · 2015 · PLoS ONE
  98. Cost of managing meningitis and encephalitis among adult patients in the United States of America
    Joan-Miquel Balada-Llasat, Ning An Rosenthal, Rodrigo Hasbun, Louise Zimmer, Christine C. Ginocchio, Steven B. Duff, Jessica Allison, Samuel A. Bozzette · 2018 · International Journal of Infectious Diseases
  99. Routine vaccination against MenB
    Patricia Kaaijk, Arie VAN DER ENDE, Willem Luytjes · 2013 · Human Vaccines & Immunotherapeutics
  100. Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis
    Marisa K. Holubar, Maria Christina Stavroulakis, Yvonne Maldonado, John P. A. Ioannidis, Despina G. Contopoulos‐Ioannidis · 2017 · PLoS ONE